ArticleHaematologica2010
Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database.
Article in Haematologica, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 3 syntheses or guidelines pooled it, 234 citations in OpenAlex.
- The thrombotic burden of high-risk immune thrombocytopenia patients receiving second-line treatments: a systematic review.Rheumatology (Oxford, England) · 2026Pooled it
- Ischemic stroke/transient ischemic attack in adults with primary immune thrombocytopenia: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Pooled it
- Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies.International journal of hematology · 2016Pooled it
- Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.American journal of hematology · 2020Trial
- Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies.British journal of haematology · 2019Trial
- Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.International journal of hematology · 2015Trial
- Autoimmune-associated thrombosis: mechanisms, population burden, and prevention strategies.The Lancet regional health. Europe · 2026Review
- Association of carotid intima media thickness with cardiovascular disease risk in immune thrombocytopenia.International journal of hematology · 2026Article
- Early Use of Fostamatinib in Immune Thrombocytopenia.Advances in therapy · 2026Article
- Cardiovascular and comorbid risk factors for thrombosis in primary immune thrombocytopenia: a single-center retrospective study.Research and practice in thrombosis and haemostasis · 2026Article
- Thrombosis in adult primary immune thrombocytopenia in Korea: incidence and risk factors in a 20-year retrospective cohort.Annals of hematology · 2026Article
- No significant increase in thrombotic risk following the widespread adoption of TPO-RAs in ITP: A comparative study.Global medical genetics · 2026Article
- Refractory Primary Immune Thrombocytopenia With Bleeding and Thrombosis: A Case Report.The American journal of case reports · 2026Article
- [Construction and evaluation of a thrombosis risk prediction model in patients with primary immune thrombocytopenia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Outcomes, Treatment Patterns, and Resource Use in European Adults with Immune Thrombocytopenia Treated with Avatrombopag.TH open : companion journal to thrombosis and haemostasis · 2026Article
- Development and Validation of a Novel Thrombosis Prediction Model for Adult Immune Thrombocytopenia (ITP-THROMBO).Journal of blood medicine · 2026Article
- Spontaneous Lingual Bleeding and Intracerebral Hemorrhage in a Young Adult with Immune Thrombocytopenia (ITP): A Rare Case Report and Brief Recent Update on Treatment.Cardiovascular & hematological disorders drug targets · 2026Review
- Arterial Thrombosis in Patients with Primary Immune Thrombocytopenia: A Nationwide StudyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025Article
- Evaluating rilzabrutinib in the treatment of immune thrombocytopenia.Immunotherapy · 2025Review
- Stroke, idiopathic thrombocytopenic purpura and avatrombopag: two cases of coincident events.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe risk of thromboembolic events in adults with primary immune thrombocytopenia has been little investigated despite findings of increased susceptibility in other thrombocytopenic autoimmune conditions. The objective of this study was to evaluate the risk of thromboembolic events among adult patients with and without primary immune thrombocytopenia in the UK General Practice Research Database. DESIGN AND
methodsUsing the General Practice Research Database, 1,070 adults (>or=18 years) with coded records for primary immune thrombocytopenia first referenced between January 1(st) 1992 and November 30(th) 2007, and having at least one year pre-diagnosis and three months post-diagnosis medical history were matched (1:4 ratio) with 4,280 primary immune thrombocytopenia disease free patients by age, gender, primary care practice, and pre-diagnosis observation time. The baseline prevalence and incidence rate of thromboembolic events were quantified, with comparative risk modelled by Cox's proportional hazards regression.
resultsOver a median 47.6 months of follow-up (range: 3.0-192.5 months), adjusted hazard ratios of 1.58 (95% CI, 1.01-2.48), 1.37 (95% CI, 0.94-2.00), and 1.41 (95% CI, 1.04-1.91) were found for venous, arterial, and combined (arterial and venous) thromboembolic events, respectively, when comparing the primary immune thrombocytopenia cohort with the primary immune thrombocytopenia disease free cohort. Further event categorization revealed an elevated incidence rate for each occurring venous thromboembolic subtype among the adult patients with primary immune thrombocytopenia.
conclusionsPatients with primary immune thrombocytopenia are at increased risk for venous thromboembolic events compared with patients without primary immune thrombocytopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.